Therapeutic Strategies for Diabetic Neuropathy
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Diabetes is the leading cause of peripheral neuropathy globally. Duration of diabetes, glycemic control, and preexisting cardiovascular risk factors independently correlate with the development and progression of diabetic peripheral neuropathy as well as cardiovascular autonomic neuropathy. The pathogenesis of diabetic neuropathy remains unclear, although insulin resistance, oxidative stress, mitochondrial dysfunction, abnormal glucose metabolism, advanced glycation end products, neurotrophic factors, and protein kinase C activation all may play a role. Strict glycemic control remains the only available treatment option, although other treatments are in development. Multiple options are available for symptom management. In this article, we review factors associated with development and progression of diabetic neuropathy and discuss available treatment options.
- Martyn CN, Hughes RA: Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997, 62:310–318. CrossRef
- Abbott CA, Carrington AL, Ashe H, et al.: The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002, 19:377–384. CrossRef
- Beiswenger KK, Calcutt NA, Mizisin AP: Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 2008, 110:351–362. CrossRef
- Dyck PJ, Kratz KM, Karnes JL, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817–824.
- Dyck PJ, Davies JL, Wilson DM, et al.: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999, 22:1479–1486. CrossRef
- The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995, 122:561–568.
- Martin CL, Albers J, Herman WH, et al.: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340–344. CrossRef
- Tesfaye S, Chaturvedi N, Eaton SE, et al.: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341–350. CrossRef
- Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995, 38:869–880.
- Franklin GM, Kahn LB, Baxter J, et al.: Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990, 131:633–643.
- Singleton JR, Smith AG, Bromberg MB: Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448–1453. CrossRef
- Sumner CJ, Sheth S, Griffin JW, et al.: The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108–111.
- Dyck PJ, Klein CJ, Weigand SD: Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve 2007, 36:536–541. CrossRef
- Barr EL, Wong TY, Tapp RJ, et al.: Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999–2000 AusDiab. Diabetes Care 2006, 29:1114–1116. CrossRef
- Forrest KY, Maser RE, Pambianco G, et al.: Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997, 46:665–670. CrossRef
- Elliott J, Tesfaye S, Chaturvedi N, et al.: Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009, 32:1896–1900. This study evaluated risk factors for the development of diabetic neuropathy in a large, prospectively evaluated cohort (EuroDiab Prospective Complications Study) and described the significant association between cardiovascular risk factors and neuropathy, independent of glycemic control. These factors require further intensive study and likely will prove to be important in controlling and treating diabetic neuropathy.
- Harris M, Eastman R, Cowie C: Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993, 16:1446–1452. CrossRef
- Mitchell BD, Hawthorne VM, Vinik AI: Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990, 13:434–437. CrossRef
- Maser RE, Steenkiste AR, Dorman JS, et al.: Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989, 38:1456–1461.
- Wiggin TD, Sullivan KA, Pop-Busui R, et al.: Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634–1640. CrossRef
- Maser RE, Pfeifer MA, Dorman JS, et al.: Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med 1990, 150:1218–1222. CrossRef
- Valensi P, Sachs RN, Harfouche B, et al.: Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001, 24:339–343. CrossRef
- Maser RE, Mitchell BD, Vinik AI, Freeman R: The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003, 26:1895–1901. CrossRef
- Kempler P, Tesfaye S, Chaturvedi N, et al.: Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002, 19:900–909. CrossRef
- The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998, 41:416–423.
- Witte DR, Tesfaye S, Chaturvedi N, et al.: Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005, 48:164–171. CrossRef
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977–986.
- Albers JW, Herman WH, Pop-Busui R, et al.: Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007, 30:2613–2618. This study highlights the impact of strict glycemic control on nerve injury even in patients without clinical or electrophysiologic evidence of neuropathy.
- Pop-Busui R, Low PA, Waberski BH, et al.: Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886–2893. CrossRef
- Dyck PJ, Davies JL, Clark VM, et al.: Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006, 29:2282–2288. CrossRef
- Oates PJ: Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008, 9:14–36. This recent article reviews the evidence supporting a role for the aldose reductase pathway in the pathogenesis of diabetic neuropathy and the potential for aldose reductase inhibition as a therapeutic option.
- Heesom AE, Millward A, Demaine AG: Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998, 64:213–216. CrossRef
- Greene DA, Arezzo JC, Brown MB: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999, 53:580–591.
- Gabbay KH: Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? Curr Diab Rep 2004, 4:405–408. CrossRef
- Goto Y, Hotta N, Shigeta Y, et al.: Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 1995, 49:269–277.
- Bril V, Buchanan RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006, 29:68–72. CrossRef
- Hotta N, Toyota T, Matsuoka K, et al.: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001, 24:1776–1782. CrossRef
- Bril V, Hirose T, Tomioka S, Buchanan R: Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009, 32:1256–1260. CrossRef
- Apfel SC, Schwartz S, Adornato BT, et al.: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000, 284:2215–2221.
- Apfel SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002, 50:393–413. CrossRef
- Simovic D, Isner JM, Ropper AH, et al.: Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001, 58:761–768. CrossRef
- Murakami T, Arai M, Sunada Y, Nakamura A: VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006, 8:773–781. CrossRef
- Carmeliet P, Storkebaum E: Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002, 13:39–53. CrossRef
- Ropper AH, Gorson KC, Gooch CL, et al.: Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009, 65:386–393. CrossRef
- Freeman R, Durso-Decruz E, Emir B: Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008, 31:1448–1454. CrossRef
- Kajdasz DK, Iyengar S, Desaiah D, et al.: Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007, 29 Suppl:2536–2546.
- Wernicke JF, Pritchett YL, D’Souza DN, et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411–1420. CrossRef
- Tesfaye S: Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 2009, 3:136–143. CrossRef
- Rauck RL, Shaibani A, Biton V, et al.: Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007, 23:150–158. CrossRef
- Wymer JP, Simpson J, Sen D, Bongardt S: Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009, 25:376–385. CrossRef
- Baron R, Mayoral V, Leijon G, et al.: 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009, 25:1663–1676. CrossRef
- Therapeutic Strategies for Diabetic Neuropathy
Current Neurology and Neuroscience Reports
Volume 10, Issue 2 , pp 92-100
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Peripheral neuropathy
- Cardiac autonomic neuropathy
- Glycemic control
- Cardiovascular risk factors
- Industry Sectors